Specialty Drug Pricing and Out-of-Pocket Spending on Orally Administered Anticancer Drugs in Medicare Part D, 2010 to 2019

Stacie B. Dusetzina · Haiden A. Huskamp · Nancy Lynn Keating

92 citations0/0 files storedJAMA

No readable copy stored yet — this record is metadata only.

No open-access location is known for this record yet.

Literature note Cite in a project Citation map

Economic and Financial Impacts of Cancer Healthcare Policy and Management Pharmaceutical Economics and Policy

Abstract

This study describes point-of-sale prices for orally administered anticancer drugs offered through Medicare Part D and out-of-pocket changes in spending as a result of decreasing coinsurance and price changes between 2010 and 2019.

Paper brief

Loading…

Cite this work

Citation unavailable for this work.

BibTeX RIS CSL-JSON

No public copy is stored for this record, so only the metadata is cited.

Citations in this library

Citation map →

Stored only when both papers are in the corpus — 92 citations exist upstream.

References

1998The Medicare Payment Advisory Commission.2015Pricing in the Market for Anticancer Drugs 2015Five Years of Cancer Drug Approvals 2017How Much Longer Will We Put Up With $100,000 Cancer Drugs?2013Market spiral pricing of cancer drugs

Cited by

2022Association of Medical Financial Hardship and Mortality Among Cancer Survivors in the United States 2022Many Medicare Beneficiaries Do Not Fill High-Price Specialty Drug Prescriptions

Explore the map →

Papers that cite the same references — the relational fallback while embeddings are still backfilling.

Imported from OpenAlex (CC0) — nothing here is generated.